Glaukos (GKOS) Stock Soars After Blowout Q3 Earnings Beat

Glaukos Corporation stocks have been trading up by 33.65 percent amid strong investor optimism surrounding its latest clinical advancements.

Live Update At 16:47:13 EDT: On Thursday, October 29, 2026 Glaukos Corporation stock [NYSE: GKOS] is trending up by 33.65%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

GKOS has turned into a textbook momentum chart after its earnings shocker. On 2026/10/28, Glaukos dropped its Q3 numbers: EPS of $0.47 versus a -$0.09 consensus and revenue around $211M versus $168.1M expected. That kind of beat typically forces traders to reprice a name fast, and GKOS played along.

Look at the daily chart. Before the print, GKOS was chopping in the mid‑$160s to high‑$170s. The day after earnings, the stock jumped from a $181.94 open to a $242.48 close on 2026/10/29. That’s a massive range and confirms aggressive buying, not just a slow grind.

Intraday on 2026/10/29, GKOS opened near $212.83, briefly flushed to $207.41, then ripped all day, topping at $243.71 into the close. That’s classic earnings‑gap continuation — dip buyers stepped in early, shorts got squeezed late.

Under the hood, Glaukos is still a high‑growth, low‑profitability story. Revenue over the last year is about $507.4M with a fat 60.7% gross margin, but margins below the line are negative and returns on equity and assets are still in the red. For traders, that mix — fast top‑line growth plus improving earnings — is often the fuel behind multi‑quarter momentum, but it demands tight risk management once the move gets extended.

Why Traders Are Watching GKOS Momentum

GKOS is suddenly on every growth trader’s radar, and the reason is simple: the numbers finally matched the story. Glaukos has talked for years about building a glaucoma, corneal, and retinal platform. Q3 2026 is where that narrative showed up clearly in the P&L.

The Q3 earnings beat was not a tiny surprise; it was a reset. Going from a Street view of -$0.09 EPS to an actual $0.47, with revenue blasting past estimates to about $211M, tells traders that iDose TR and Epioxa are scaling faster than many models assumed. That kind of upside forces funds and quant models to chase.

Then management added gasoline with guidance. Glaukos now sees FY26 revenue at $775M–$785M and FY27 at $1.0B, versus prior consensus around $691.7M and $852.5M. When a medtech name like GKOS lays out a path toward $1.0B in sales, traders pay attention because it helps anchor higher valuations even after a sharp run.

Clinical news is reinforcing the move. Phase 4 data showed iDose TR, when used with cataract surgery for open‑angle glaucoma or ocular hypertension, delivered statistically and clinically meaningful extra pressure reduction versus surgery alone, with a favorable three‑month safety profile. That supports broader use of iDose TR and reduces fear of a post‑launch stumble.

At the same time, three‑year Phase 3 extension data for Epioxa showed durable improvements in corneal curvature and visual acuity in keratoconus, with no need for repeat treatment and a clean long‑term safety readout. For Glaukos, that strengthens the corneal disorders franchise and gives traders more confidence that revenue from Epioxa can be sticky rather than a one‑cycle bump.

Layer on the RevOpsis deal — exclusive rights to RO-104 and the RevMod platform for up to four new retinal biologics — and GKOS now touches glaucoma, cornea, and retina with credible assets. BTIG lifting its GKOS target to $205 and Mizuho pushing theirs to $190 only adds to the sense that the Street is still leaning bullish even after a roughly 14% post‑print share pop.

Conclusion

GKOS is a strong example of how fundamentals and price action can suddenly snap into alignment. Glaukos delivered a huge Q3 beat, reset expectations higher with FY26 and FY27 revenue targets, and backed it up with clean data on both iDose TR and Epioxa. The stock reaction — a surge from the $170s to the mid‑$240s in a few days — shows how quickly a name can rerate once the market believes the growth story.

For active traders, GKOS now sits in classic momentum territory. The daily chart shows a powerful earnings gap and continuation, while intraday action reveals steady demand throughout the session. That’s the kind of behavior many in the Tim Sykes community look for: strong catalyst, volume, and a clear trend.

At the same time, Glaukos still carries high growth valuations, negative historical margins, and heavy expectations embedded in that new $1.0B revenue target for 2027. That makes discipline crucial. As Tim Sykes loves to remind traders, “The market rewards preparation, not hope — study the patterns, respect the risk, and never fall in love with a stock.” As millionaire penny stock trader and teacher Tim Sykes, says, “The goal is not to win every trade but to protect your capital and keep moving forward.” This mindset is essential when navigating a fast-moving, high-expectation name like GKOS.

GKOS is offering a live case study in how strong news and tight execution can drive a powerful move. Use it to sharpen your trading playbook, not as a substitute for your own research and risk management.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks